A Mab A Case Study In Bioprocess Development ((install)) Here
A-Mab Case Study
The , published by the CMC Biotech Working Group , is a foundational document in the biopharmaceutical industry. It serves as a mock regulatory submission to demonstrate how Quality by Design (QbD) principles from ICH guidelines (Q8, Q9, and Q10) can be applied to the development of a monoclonal antibody . 1. Identify Quality Attributes
- Molecule: IgG1 with moderate aggregation tendency, glycosylation requiring high G0F content.
- Chosen platform: CHO-S stable clone, fed-batch process targeting 6 g/L titer via optimized feed, 14-day run.
- Downstream: Protein A capture (milligram per mL DBC optimized), CEX polishing to remove basic variants, AEX flow-through for HCP clearance, nanofiltration for viral removal, final formulation 150 mg/mL in histidine/sucrose/polysorbate.
- Key outcomes: overall recovery 55–65%, aggregate <1%, HCP <100 ppm, projected COGs $50–150/g (illustrative).
- Process risks and mitigations: proteolysis controlled by low temperature harvest; methionine oxidation minimized by antioxidant addition; resin leachables handled by robust cleaning and analytics.
Innovation:
The team adjusts the buffer to 10 mM histidine (pH 6.0) with 150 mM arginine and 5% trehalose. This combination reduces viscosity to 8 cP at 120 mg/mL, allowing efficient TFF. A Mab A Case Study In Bioprocess Development
Proposes methods for real-time release testing and lifecycle management to maintain consistent quality throughout commercial manufacturing. Relevant Resources Quality By Design for Monoclonal Antibodies, Part 1 A-Mab Case Study The , published by the
3.1 Capture Chromatography (Protein A Affinity)
Design Space
: A major highlight is the definition of a scale-independent design space for the production bioreactor, leveraging data from small-scale models (2L) to support commercial-scale operations. Innovation: The team adjusts the buffer to 10
The Candidate:
Humanized IgG1 (pI 8.2), expressed in CHO-K1 cells. The Challenge: High aggregate formation (>15%) and low viral clearance capability during Protein A capture.
This content is suitable for a bioprocess engineering blog, a technical whitepaper, or an educational slide deck.
